Nele Henrike Thomas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nele Henrike Thomas has a total of 157 co-authors. Here are the top co-authors by number of shared publications:
- Anika Großhennig
Institute for Biostatistics, Hannover Medical School , Hannover
4 shared publications - Armin Koch
Institute for Biostatistics, Hannover Medical School, Hannover, Germany
4 shared publications - Xiaofei Liu
Institute for Biostatistics, Hannover Medical School, Hannover, Germany
3 shared publications - Andreas J. Rieth
Department of Cardiology, Justus Liebig University Giessen, Bad Nauheim, Germany
2 shared publications - Dominik Berliner
Department of Cardiology and Angiology, Hannover Medical School , Hannover
2 shared publications Heiko von der Leyen
Orgenesis, Inc, Germantown, MD, USA
2 shared publications
Latest Publications
- Open Access
- 28 May 2026
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 19 (7) , e014396
DIGIT-HF: Results From the Win Ratio Analyses
- 28 May 2026
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 19 (7) , e014396
Open AccessDIGIT-HF: Results From the Win Ratio Analyses
- Open Access
- 17 February 2026
- Published by Wiley in Pharmaceutical Statistics
- Vol. 25 (2) , e70078
A Statistical Concept for Conditional Marketing Authorisation Based on the Intermediate and Final Outcomes of a Single Confirmatory Randomised Clinical Trial
Conditional marketing authorisation (CMA) is a path to early market access of new medicines addressing an unmet medical need in the European Union (EU), and similar concepts exist in other regulatory regions. For justifying a CMA, the benefit‐risk ratio has to be positive, and the applicant must be able to provide comprehensive data post‐authorisation for converting the CMA to a full marketing authorisation (MA). A recent proposal is to plan a single randomised clinical trial with interim analyses and base the decision for CMA and full MA on an intermediate and a final primary endpoint. To control the study‐wise type‐1‐error (T1E), the dual primary endpoint concept, essentially a Bonferroni‐split of the study‐wise T1E between the intermediate and final endpoints, has been proposed. We argue that the resulting statistical definition of formal study success is not in line with clinical assessment of the overall trial outcome. Consistent with the European Medicines Agency (EMA) guideline on multiplicity issues in clinical trials, the intermediate and final endpoints should be co‐primary, and we propose that each is assessed with a standard group sequential design. We illustrate our proposal using an oncology phase III trial with complete remission (CR) as the intermediate and overall survival (OS) as the final primary endpoint. Based on the example, we demonstrate that our proposal is a valid and flexible alternative with minimal to no impact on costs in terms of sample size or timing of the interim analysis intended for applying for a CMA but it improves the interpretation of the overall trial outcome.
- 17 February 2026
- Published by Wiley in Pharmaceutical Statistics
- Vol. 25 (2) , e70078
Open AccessA Statistical Concept for Conditional Marketing Authorisation Based on the Intermediate and Final Outcomes of a Single Confirmatory Randomised Clinical Trial
Conditional marketing authorisation (CMA) is a path to early market access of new medicines addressing an unmet medical need in the European Union (EU), and similar concepts exist in other regulatory regions. For justifying a CMA, the benefit‐risk ratio has to be positive, and the applicant must be able to provide comprehensive data post‐authorisation for converting the CMA to a full marketing authorisation (MA). A recent proposal is to plan a single randomised clinical trial with interim analyses and base the decision for CMA and full MA on an intermediate and a final primary endpoint. To control the study‐wise type‐1‐error (T1E), the dual primary endpoint concept, essentially a Bonferroni‐split of the study‐wise T1E between the intermediate and final endpoints, has been proposed. We argue that the resulting statistical definition of formal study success is not in line with clinical assessment of the overall trial outcome. Consistent with the European Medicines Agency (EMA) guideline on multiplicity issues in clinical trials, the intermediate and final endpoints should be co‐primary, and we propose that each is assessed with a standard group sequential design. We illustrate our proposal using an oncology phase III trial with complete remission (CR) as the intermediate and overall survival (OS) as the final primary endpoint. Based on the example, we demonstrate that our proposal is a valid and flexible alternative with minimal to no impact on costs in terms of sample size or timing of the interim analysis intended for applying for a CMA but it improves the interpretation of the overall trial outcome.
- Open Access
- 6 May 2025
- Published by Elsevier in Journal of Dentistry
- Vol. 158, 105808
Systematic review and meta-analysis on marginal bone loss of dental implants placed in augmented or pristine bone sites: Findings from clinical long-term studies
- 6 May 2025
- Published by Elsevier in Journal of Dentistry
- Vol. 158, 105808
Open AccessSystematic review and meta-analysis on marginal bone loss of dental implants placed in augmented or pristine bone sites: Findings from clinical long-term studies
- Open Access
- 22 May 2023
- Published by Wiley in Pharmaceutical Statistics
- Vol. 22 (5) , 836-845
How to avoid concerns with the interpretation of two primary endpoints if significant superiority in one is sufficient for formal proof of efficacy
Formal proof of efficacy of a drug requires that in a prospective experiment, superiority over placebo, or either superiority or at least non‐inferiority to an established standard, is demonstrated. Traditionally one primary endpoint is specified, but various diseases exist where treatment success needs to be based on the assessment of two primary endpoints. With co‐primary endpoints, both need to be “significant” as a prerequisite to claim study success. Here, no adjustment of the study‐wise type‐1‐error is needed, but sample size is often increased to maintain the pre‐defined power. Studies that use an at‐least‐one concept have been proposed where study success is claimed if superiority for at least one of the endpoints is demonstrated. This is sometimes also called the dual primary endpoint concept, and an appropriate adjustment of the study‐wise type‐1‐error is required. This concept is not covered in the European Guideline on multiplicity because study success can be claimed if one endpoint shows significant superiority, despite a possible deterioration in the other. In line with Röhmel's strategy, we discuss an alternative approach including non‐inferiority hypotheses testing that avoids obvious contradictions to proper decision‐making. This approach leads back to the co‐primary endpoint assessment, and has the advantage that minimum requirements for endpoints can be modeled flexibly for several practical needs. Our simulations show that, if planning assumptions are correct, the proposed additional requirements improve interpretation with only a limited impact on power, that is, on sample size.
- 22 May 2023
- Published by Wiley in Pharmaceutical Statistics
- Vol. 22 (5) , 836-845
Open AccessHow to avoid concerns with the interpretation of two primary endpoints if significant superiority in one is sufficient for formal proof of efficacy
Formal proof of efficacy of a drug requires that in a prospective experiment, superiority over placebo, or either superiority or at least non‐inferiority to an established standard, is demonstrated. Traditionally one primary endpoint is specified, but various diseases exist where treatment success needs to be based on the assessment of two primary endpoints. With co‐primary endpoints, both need to be “significant” as a prerequisite to claim study success. Here, no adjustment of the study‐wise type‐1‐error is needed, but sample size is often increased to maintain the pre‐defined power. Studies that use an at‐least‐one concept have been proposed where study success is claimed if superiority for at least one of the endpoints is demonstrated. This is sometimes also called the dual primary endpoint concept, and an appropriate adjustment of the study‐wise type‐1‐error is required. This concept is not covered in the European Guideline on multiplicity because study success can be claimed if one endpoint shows significant superiority, despite a possible deterioration in the other. In line with Röhmel's strategy, we discuss an alternative approach including non‐inferiority hypotheses testing that avoids obvious contradictions to proper decision‐making. This approach leads back to the co‐primary endpoint assessment, and has the advantage that minimum requirements for endpoints can be modeled flexibly for several practical needs. Our simulations show that, if planning assumptions are correct, the proposed additional requirements improve interpretation with only a limited impact on power, that is, on sample size.
- Open Access
- 22 February 2022
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 9 (3) , 351-362
Validity and reliability of the German multidimensional fatigue inventory in spinal muscular atrophy
Objective: Fatigue is a common and burdensome symptom of spinal muscular atrophy. Given its complex interactions, different dimensions of fatigue need to be investigated. The Multidimensional Fatigue Inventory is a widely used instrument that captures five distinct dimensions. The aim of this study was to investigate the validity and reliability of the German Multidimensional Fatigue Inventory in spinal muscular atrophy and to evaluate the presence of clinically relevant fatigue.Methods: One hundred and forty adult spinal muscular atrophy patients completed the Multidimensional Fatigue Inventory in a nationwide, multicenter, cross‐sectional study. Structural validity was explored using principal component analysis. Cronbach’s α was calculated to evaluate internal consistency. Convergent validity was assessed by correlation with a Visual Analog Scale for fatigue and the EuroQol‐Five Dimension‐Five Level Scale as a measure of quality of life.Results: The original five‐component model of the questionnaire constituted an acceptable fit. Internal consistency and convergent validity of general, physical, mental fatigue, and reduced activity were good. We observed a floor effect for mental fatigue. While physical fatigue exceeded the cutoff for clinically relevant fatigue, all dimensions but reduced motivation correlated negatively with quality of life. Age, depression, and ≥4 copies of the survival motor neuron 2 gene were associated with higher general/physical fatigue; unemployed participants reported higher scores for reduced activity/motivation.Interpretation: The Multidimensional Fatigue Inventory is a valid and reliable instrument to assess different dimensions of fatigue in spinal muscular atrophy. Fatigue is a relevant problem in spinal muscular atrophy and its assessment should be incorporated into standard care.
- 22 February 2022
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 9 (3) , 351-362
Open AccessValidity and reliability of the German multidimensional fatigue inventory in spinal muscular atrophy
Objective: Fatigue is a common and burdensome symptom of spinal muscular atrophy. Given its complex interactions, different dimensions of fatigue need to be investigated. The Multidimensional Fatigue Inventory is a widely used instrument that captures five distinct dimensions. The aim of this study was to investigate the validity and reliability of the German Multidimensional Fatigue Inventory in spinal muscular atrophy and to evaluate the presence of clinically relevant fatigue.Methods: One hundred and forty adult spinal muscular atrophy patients completed the Multidimensional Fatigue Inventory in a nationwide, multicenter, cross‐sectional study. Structural validity was explored using principal component analysis. Cronbach’s α was calculated to evaluate internal consistency. Convergent validity was assessed by correlation with a Visual Analog Scale for fatigue and the EuroQol‐Five Dimension‐Five Level Scale as a measure of quality of life.Results: The original five‐component model of the questionnaire constituted an acceptable fit. Internal consistency and convergent validity of general, physical, mental fatigue, and reduced activity were good. We observed a floor effect for mental fatigue. While physical fatigue exceeded the cutoff for clinically relevant fatigue, all dimensions but reduced motivation correlated negatively with quality of life. Age, depression, and ≥4 copies of the survival motor neuron 2 gene were associated with higher general/physical fatigue; unemployed participants reported higher scores for reduced activity/motivation.Interpretation: The Multidimensional Fatigue Inventory is a valid and reliable instrument to assess different dimensions of fatigue in spinal muscular atrophy. Fatigue is a relevant problem in spinal muscular atrophy and its assessment should be incorporated into standard care.